Trial Profile
A Randomized Controlled Trial of Donepezil for REM Enhancement and Behavioral Change in Autism
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 21 Dec 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 12 Dec 2013 Planned number of patients changed from 180 to 90 as reported by ClinicalTrials.gov.
- 14 Aug 2013 New trial record